Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Data on Auvelity demonstrating improved functioning in major depressive disorder Data on Sunosi demonstrating improved cognitive function in patients with excessive daytime sleepiness associated with...
April 21, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting

NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
February 22, 2023 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe

Axsome to receive an upfront payment of $66 million, and is eligible to receive sales-based and other milestones totaling up to $101 million Pharmanovia is responsible for all ongoing and future...
November 03, 2022 16:30 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Reports Third Quarter 2022 Financial Results

PHILADELPHIA, PA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
September 07, 2022 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepiness in Narcolepsy or Obstructive Sleep Apnea Patients with a History of Depression in the Journal of Psychiatric Research

NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
June 28, 2022 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders

NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
May 25, 2022 03:17 ET | Source: Global Market Insights Inc.

Sleep Tech Devices Market to cross USD 67 billion by 2030, says Global Market Insights Inc.

Selbyville, Delaware, May 25, 2022 (GLOBE NEWSWIRE) -- The sleep tech devices market value is expected to reach USD 67 billion by 2030, according to a new research report by Global Market Insights...
May 13, 2022 08:30 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Announces $3.9 Million Registered Direct Offering

PHILADELPHIA, PA, May 13, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
May 12, 2022 08:30 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR

PHILADELPHIA, PA, May 12, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
January 12, 2022 06:30 ET | Source: Global Market Insights Inc.

Sleep Disorder Market revenue to cross USD 20.5 Bn by 2027: Global Market Insights Inc.

Selbyville, Delaware, Jan. 12, 2022 (GLOBE NEWSWIRE) -- The sleep disorder market size is anticipated to record a valuation of USD 20.5 billion by 2027, according to the most recent study by...